{"id":4654,"date":"2024-11-14T13:00:10","date_gmt":"2024-11-14T03:00:10","guid":{"rendered":"\/americas\/?p=4654"},"modified":"2024-11-14T13:02:34","modified_gmt":"2024-11-14T03:02:34","slug":"stockhead-long-shortz-no-nerves-as-company-enters-us-market","status":"publish","type":"post","link":"\/americas\/stockhead-long-shortz-no-nerves-as-company-enters-us-market\/","title":{"rendered":"Stockhead Long Shortz | No nerves as company enters US market"},"content":{"rendered":"<div class=\"xdj266r x11i5rnm xat24cr x1mh8g0r x1vvkbs x126k92a\">\n<div dir=\"auto\">This week <span class=\"html-span xdj266r x11i5rnm xat24cr x1mh8g0r xexx8yu x4uap5 x18d9i69 xkhd6sd x1hl2dhg x16tdsg8 x1vvkbs\"><span class=\"xt0psk2\">Orthocell<\/span><\/span> announced the appointment to two new US-based executives as the Company prepares to enter the US market with its nerve repair product, Remplir\u2122.<\/div>\n<\/div>\n<div class=\"x11i5rnm xat24cr x1mh8g0r x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\"><\/div>\n<\/div>\n<div class=\"x11i5rnm xat24cr x1mh8g0r x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\">Orthocell Chairman John Van Der Wielen spoke with Stockhead to discuss the Company&#8217;s strategic positioning ahead of its US market entry, sharing insights on why Remplir represents a compelling investment opportunity.<\/div>\n<\/div>\n<div class=\"x11i5rnm xat24cr x1mh8g0r x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\"><\/div>\n<div dir=\"auto\">Here&#8217;s an excerpt:<\/div>\n<div dir=\"auto\"><\/div>\n<\/div>\n<div class=\"x11i5rnm xat24cr x1mh8g0r x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\"><em>&#8220;The difference between Orthocell is you&#8217;ve got a product that&#8217;s already been used in human bodies. There&#8217;s over $35 million of cash on the balance sheet, and it&#8217;s already in revenue with existing regulatory approval. It has crossed that threshold between this amazing concept and something that&#8217;s actually generating revenue&#8230; it&#8217;s a very low risk biotech compared to the majority of other smaller cap stocks. People are realising this is right on the threshold of coming into profit and significant growth.&#8221;<\/em><\/div>\n<\/div>\n<div dir=\"auto\"><\/div>\n<div dir=\"auto\"><a href=\"https:\/\/bit.ly\/OCC-Stockhead-JVW\">Click to view the interview.\u00a0<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell Chairman John Van Der Wielen spoke with Stockhead to discuss the Company&#8217;s strategic positioning ahead of its US market entry, sharing insights on why Remplir represents a compelling investment opportunity.<\/p>\n","protected":false},"author":2,"featured_media":2613,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4654","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video"],"aioseo_notices":[],"_links":{"self":[{"href":"\/americas\/wp-json\/wp\/v2\/posts\/4654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/americas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/americas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/comments?post=4654"}],"version-history":[{"count":1,"href":"\/americas\/wp-json\/wp\/v2\/posts\/4654\/revisions"}],"predecessor-version":[{"id":4655,"href":"\/americas\/wp-json\/wp\/v2\/posts\/4654\/revisions\/4655"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/media\/2613"}],"wp:attachment":[{"href":"\/americas\/wp-json\/wp\/v2\/media?parent=4654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/categories?post=4654"},{"taxonomy":"post_tag","embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/tags?post=4654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}